Patient characteristics and response to pembrolizumab
| . | Patient . | ||||
|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | 5 . | |
| Prior therapies, n | 2 | 4 | 2 | 3 | 2 |
| Prior anti-CD19 CAR-T cells | No | Yes | No | No | No |
| Cycles of pembrolizumab, n | 32 | 9 | 14 | 3 | 5 |
| Best radiographic response | CR (ongoing*) | CR (ongoing*) | PR | PD | PD |
| . | Patient . | ||||
|---|---|---|---|---|---|
| 1 . | 2 . | 3 . | 4 . | 5 . | |
| Prior therapies, n | 2 | 4 | 2 | 3 | 2 |
| Prior anti-CD19 CAR-T cells | No | Yes | No | No | No |
| Cycles of pembrolizumab, n | 32 | 9 | 14 | 3 | 5 |
| Best radiographic response | CR (ongoing*) | CR (ongoing*) | PR | PD | PD |
PD, progressive disease.
For patient 1, CR >2 years; for patient 2, CR >6 months.